Synthetic organic

InformationACT-389949 is a potent, selective agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX) with EC50 of 3 nM for FPR2/ALX internalization into monocytes. ACT-389949 has potential for inflammatory disorders.

InformationACT-389949 is a potent, selective agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX) with EC50 of 3 nM for FPR2/ALX internalization into monocytes. ACT-389949 has potential for inflammatory disorders.

InformationACT-389949 is a potent, selective agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX) with EC50 of 3 nM for FPR2/ALX internalization into monocytes. ACT-389949 has potential for inflammatory disorders.

ACT-660602.

ACT-660602.

ACT-777991.

ACT-777991.

acumapimod.

acumapimod.

InformationACY-738 inhibitsHDAC6with low nanomolar potency (IC50=1.7 nM) and a selectivity of 60- to 1500-fold over class I HDACs.TargetsHDAC6 (Cell-free) 1.7 nMIn vivoACY-738 induces dramatic increases in α-tubulin acetylation in brain and

InformationACY-738 inhibitsHDAC6with low nanomolar potency (IC50=1.7 nM) and a selectivity of 60- to 1500-fold over class I HDACs.TargetsHDAC6 (Cell-free) 1.7 nMIn vivoACY-738 induces dramatic increases in α-tubulin acetylation in brain and

InformationACY-738 inhibitsHDAC6with low nanomolar potency (IC50=1.7 nM) and a selectivity of 60- to 1500-fold over class I HDACs.TargetsHDAC6 (Cell-free) 1.7 nMIn vivoACY-738 induces dramatic increases in α-tubulin acetylation in brain and